TOP TEN perturbations for 1553625_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553625_at
Selected probe(set): 225086_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553625_at (225086_at) across 6672 perturbations tested by GENEVESTIGATOR:

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.8722286
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):2.5221272
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

T-cell isolation study 11 / T-cell isolation study 6

Relative Expression (log2-ratio):-2.5043755
Number of Samples:2 / 2
Experimental T-cell isolation study 11
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.
Control T-cell isolation study 6
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.

lactic acid study 1 (hypoxia) / untreated breast epithelial cell sample

Relative Expression (log2-ratio):-2.3704567
Number of Samples:3 / 3
Experimental lactic acid study 1 (hypoxia)
Breast epithelial cells exposed to 25mM lactic acid of pH6.7 and 2% hypoxia. ATC code:
Control untreated breast epithelial cell sample
Breast epithelial cells in control media under normoxia.

SPTLC123 study 1 (siRNA) / control siRNA transfected HuH-7 cell sample

Relative Expression (log2-ratio):-2.358964
Number of Samples:3 / 3
Experimental SPTLC123 study 1 (siRNA)
Human HuH-7 hepatocarcinoma cell samples transfected with 20nM siRNA targeting SPTLC123 (serine transferase subunits 1, 2 and 3). Transfected cells were incubated for 24 hours at 37C, 5% CO2. The growth media (high-glucose, DMEM, 10% fetal bovine serum, 2 mM L-glutamine, 10 mM Hepes, and 1% penicillin-streptomycin) was replaced and cells were incubated for another 24 hours before the conditioned media (DMEM + 1% FBS + fatty acid free BSA) was added. Cells were incubated for another 24 hours prior to sampling.
Control control siRNA transfected HuH-7 cell sample
Human HuH-7 hepatocarcinoma cell samples transfected with 20nM scrambled, non-targeting siRNA. Transfected cells were incubated for 24 hours at 37C, 5% CO2. The growth media (high-glucose, DMEM, 10% fetal bovine serum, 2 mM L-glutamine, 10 mM Hepes, and 1% penicillin-streptomycin) was replaced and cells were incubated for another 24 hours before the conditioned media (DMEM + 1% FBS + fatty acid free BSA) was added. Cells were incubated for another 24 hours prior to sampling.

precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (TEL-AML1)

Relative Expression (log2-ratio):2.3257256
Number of Samples:2 / 21
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control precursor-B-ALL study 2 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

DEGS1 study 1 (siRNA) / SPTLC123 study 1 (siRNA)

Relative Expression (log2-ratio):2.2893686
Number of Samples:3 / 3
Experimental DEGS1 study 1 (siRNA)
Human HuH-7 hepatocarcinoma cell samples transfected with 20nM siRNA targeting DEGS1 (dihydroceramide desaturase). Transfected cells were incubated for 24 hours at 37C, 5% CO2. The growth media (high-glucose, DMEM, 10% fetal bovine serum, 2 mM L-glutamine, 10 mM Hepes, and 1% penicillin-streptomycin) was replaced and cells were incubated for another 24 hours before the conditioned media (DMEM + 1% FBS + fatty acid free BSA) was added. Cells were incubated for another 24 hours prior to sampling.
Control SPTLC123 study 1 (siRNA)
Human HuH-7 hepatocarcinoma cell samples transfected with 20nM siRNA targeting SPTLC123 (serine transferase subunits 1, 2 and 3). Transfected cells were incubated for 24 hours at 37C, 5% CO2. The growth media (high-glucose, DMEM, 10% fetal bovine serum, 2 mM L-glutamine, 10 mM Hepes, and 1% penicillin-streptomycin) was replaced and cells were incubated for another 24 hours before the conditioned media (DMEM + 1% FBS + fatty acid free BSA) was added. Cells were incubated for another 24 hours prior to sampling.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.1522665
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):2.0981045
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-2.094099
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.